Overview

Nolvadex is the original brand name for tamoxifen, a selective estrogen receptor modulator (SERM). In the United States, generic tamoxifen is widely used as adjuvant and metastatic therapy for hormone receptor-positive breast cancer in women and in men. It may be prescribed for ductal carcinoma in situ following surgery and radiation, and it can be used when disease has spread to other organs. Some tumors outside the breast that express estrogen receptors may also be considered in select, specialist-directed scenarios.

Because tamoxifen and its active metabolites have long half-lives, some pharmacologic effects can persist for weeks after a dose is taken. If you need information on buying and insurance coverage, jump to Prices in USD, and for the rules about prescriptions and importation see Legal status in the USA.

How it works

Tamoxifen binds competitively to estrogen receptors. In breast tissue it mainly blocks estrogen-driven proliferation, while in other tissues it can behave as a partial agonist. This tissue-selective action helps slow or stop growth of estrogen receptor-positive tumors and reduces recurrence risk after primary cancer therapy. In men with certain infertility patterns and in some women with anovulatory cycles, tamoxifen can raise pituitary gonadotropins and induce ovulation; such uses are off-label in the USA and require specialist guidance.

Dosage and how to take

Use exactly as prescribed by your oncology or specialist team. Do not change your dose on your own. Typical adult regimens include:

  • Metastatic disease: 20 mg once daily (or 10 mg twice daily). Continue while benefiting and tolerating therapy.
  • Adjuvant therapy or DCIS: often 20 mg once daily for 5 years; some plans extend beyond 5 years based on risk and tolerance.
  • Men with breast cancer: similar dosing to women, individualized by the treating oncologist.

Swallow tablets with water, with or without food, preferably at the same time each day. Do not crush or chew. Long courses are common; many patients take tamoxifen for years. For handling missed doses and overdoses, see Missed dose and overdose.

Precautions

Tamoxifen can increase the risk of endometrial changes (including hyperplasia and cancer). Seek medical attention for any abnormal vaginal bleeding, pelvic pain or pressure, or new changes in vaginal discharge. Report sudden shortness of breath, chest pain, swelling or pain in a leg, or severe headache immediately, as these could indicate thromboembolic events.

  • Eye health: rare visual changes and cataracts have been reported; obtain eye exams if symptoms arise.
  • Liver and blood tests: periodic liver function tests and blood counts are commonly monitored.
  • Bone health: tamoxifen may preserve bone in postmenopausal women but can reduce bone density in premenopausal women; your clinician may monitor accordingly.
  • Contraception: pregnancy must be avoided during therapy and for at least 2 months after the last dose. Non-hormonal contraception is generally preferred.

Pregnancy and breastfeeding are not recommended during tamoxifen therapy. For detailed restrictions, see Who should not use.

Who should not use

  • History of deep vein thrombosis or pulmonary embolism unless benefits clearly outweigh risks and are managed by a specialist.
  • Current pregnancy or breastfeeding.
  • Known hypersensitivity to tamoxifen or tablet components.
  • Concomitant coumarin anticoagulant therapy (for example, warfarin) is generally avoided due to increased bleeding risk unless managed with close monitoring.

Use extra caution in people with severe thrombophlebitis, significant hyperlipidemia, leukopenia or thrombocytopenia, prior thromboembolism, hypercalcemia (particularly with bone metastases), and certain eye disorders such as cataracts.

Side effects and monitoring

Many effects are mild and improve over time. Contact your clinician if symptoms persist or worsen.

  • Common: hot flashes, night sweats, nausea or vomiting, leg cramps, fatigue, weight changes, menstrual irregularities, and vaginal discharge.
  • Less common but important: mood changes, rash, pruritus, hair thinning, fluid retention.
  • Serious - seek urgent care: signs of blood clots (sudden leg swelling/pain, chest pain, coughing blood), stroke-like symptoms, visual disturbances, jaundice or right upper abdominal pain, heavy or unusual vaginal bleeding.

Because tamoxifen can affect liver enzymes and blood counts, periodic lab monitoring is customary throughout treatment.

Drug interactions

Always give your care team a complete list of prescription and OTC medicines, supplements, and herbals. Notable interactions include:

  • Strong CYP2D6 inhibitors (for example, paroxetine, fluoxetine, quinidine, bupropion): may reduce formation of active metabolites and blunt tamoxifen efficacy. Consider alternatives such as venlafaxine for hot flashes when appropriate.
  • Warfarin and other coumarins: increased risk of bleeding; generally avoid or monitor very closely.
  • Enzyme inducers such as rifampin, rifabutin, carbamazepine, phenobarbital, and phenytoin: can lower tamoxifen exposure.
  • St. John's wort: may reduce drug levels via enzyme induction; avoid.
  • Concomitant aromatase inhibitors (anastrozole, letrozole): typically not combined with tamoxifen; regimens are chosen alternatively based on menopausal status and clinical strategy.

Missed dose and overdose

Missed dose: If you miss a dose and it is not close to your next scheduled time, take it when remembered. If it is almost time for your next dose, skip the missed dose. Do not double up.

Overdose: Get urgent medical help. High doses have produced acute neurologic symptoms such as tremor, hyperreflexia, dizziness, and unsteady gait in some patients. Bring the medication container to the clinic or emergency department if possible.

Storage

Keep tablets at room temperature, ideally 20-25 C (68-77 F). Protect from excessive heat, moisture, and light. Store in the original container with the label intact, out of reach of children and pets.

Alternative and similar medicines

Selection depends on cancer type, menopausal status, genomic markers, prior therapy, and side effect profile. Discuss with your oncologist. Options that may be considered include:

  • SERMs: toremifene (similar to tamoxifen), raloxifene (primarily for osteoporosis and risk reduction, not standard for active breast cancer), and clomiphene (fertility use; not a cancer therapy).
  • Aromatase inhibitors: anastrozole, letrozole, and exemestane are often preferred in postmenopausal women or combined with ovarian suppression in premenopausal women.
  • Estrogen receptor downregulator: fulvestrant (injectable SERD) for advanced disease.
  • Targeted combinations: CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) or PI3K/mTOR pathway agents added to endocrine therapy for certain metastatic settings.
  • Ovarian suppression: goserelin, leuprolide used with endocrine agents in premenopausal patients.

For approximate US costs and comparisons, see Prices in USD.

Prices in USD

Retail prices vary substantially by pharmacy, brand vs generic, dosage, and whether you use coupons or insurance. Approximate cash price ranges in the USA:

  • Tamoxifen 20 mg tablets (30-count): about $6-$50 with common discount programs; some pharmacies list $15-$80 without a coupon.
  • Tamoxifen 10 mg tablets (30-count): roughly $6-$45 with discounts; retail often $12-$70.
  • Brand Nolvadex (when available): often far higher than generic, potentially $200+ per 30 tablets.
  • Anastrozole 1 mg (30-count): about $8-$150 depending on pharmacy and discounts.
  • Letrozole 2.5 mg (30-count): about $10-$200.
  • Raloxifene 60 mg (30-count): often $20-$200.
  • Fulvestrant injections: commonly $1500-$3000+ per monthly dose before insurance.

These are broad estimates, not offers. Check local pharmacies, reputable online pharmacy portals, or your insurer. Patient assistance and manufacturer copay programs may be available for some brand-only agents.

Use in sport

Selective estrogen receptor modulators, including tamoxifen, are prohibited in-competition and out-of-competition by the World Anti-Doping Agency (WADA) Prohibited List. Athletes who use tamoxifen without a legitimate therapeutic use exemption risk violations, sanctions, and disqualification. Distribution or possession without a prescription also violates US law; see Legal status in the USA.